ABSTRACT
Aims Estimate trends in levels of cannabis use among adults with and without serious psychological distress (SPD) in the United States from 2009-2019, and to ascertain whether cannabis use among individuals with SPD was associated with inpatient psychiatric hospitalization and outpatient mental health care.
Design Using multivariable logistic regression models and predictive margin methods, we estimated linear time trends in levels of cannabis use by year and SPD status and rates of psychiatric hospitalization and outpatient service use.
Setting The United States: National Survey on Drug Use and Health (NSDUH), an annual cross-sectional survey, 2009-19 public use files.
Participants 447,228 adults aged ≥ 18 years.
Measurements In the past year, self-report of any and greater-than-weekly cannabis use, any inpatient psychiatric hospitalization, and any outpatient mental health care.
Findings Rates of any and weekly-plus cannabis use increased similarly among individuals with SPD compared to those without from 2009-2014 but more rapidly in SPD from 2015-2019 (p<0.001). Among individuals with SPD, probability of psychiatric hospitalization was greater among individuals with less than weekly (5.2%, 95% CI 4.4-5.9%, p=0.011), and weekly-plus cannabis use (5.4%, 95% CI 4.6-6.1, p=0.002) compared to no use (4.1%, 95% CI 3.8-4.4%). For outpatient mental health care, no use was associated with a 27.4% probability (95% CI 26.7-8.1%) of any outpatient care, significantly less than less than weekly use (32.7% probability, 95% CI 31.3-34.1% p<0.001) and weekly-plus use (29.9% probability, 95% CI 28.3-31.5% p=0.006).
Conclusions Cannabis use is increasing more rapidly among individuals with SPD than the general population, and is associated with increased rates of psychiatric hospitalization as well as increased outpatient service use. These findings can inform policy makers looking to better tailor regulations on advertising for medical and adult use cannabis and develop public health messaging on the use of cannabis in people with mental illness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by the Dupont-Warren Fellowship from the Harvard Medical School Department of Psychiatry as well as the Cambridge Health Alliance Population Health Scholars Program
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are publicly available through the National Survey of Drug Use and Health public use files.
https://www.datafiles.samhsa.gov/dataset/national-survey-drug-use-and-health-2019-nsduh-2019-ds0001
